Diversify Wealth Management LLC Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Diversify Wealth Management LLC lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 99.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 37,441 shares of the medical research company’s stock after purchasing an additional 18,715 shares during the period. Diversify Wealth Management LLC’s holdings in Edwards Lifesciences were worth $2,749,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after acquiring an additional 2,606,950 shares in the last quarter. Nordea Investment Management AB raised its holdings in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after purchasing an additional 806,705 shares during the period. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,000 shares of company stock worth $2,195,180. 1.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EW. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. Stifel Nicolaus upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research note on Thursday. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $69.77 on Monday. The firm has a market capitalization of $41.15 billion, a PE ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. The company has a 50 day moving average price of $72.06 and a 200-day moving average price of $71.32. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the business earned $0.59 EPS. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.